Previous 10 | Next 10 |
home / stock / mrvl / mrvl articles
BofA Securities analyst Vivek Arya reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a price forecast of $...
BofA Securities analyst Vivek Arya’s top picks were Nvidia Corp (NASDAQ:NVDA) (Buy, price target of $1,100) and Broadcom Inc (NASDAQ:AVG...
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter r...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply ...
Marvell Technology, Inc (NASDAQ:MRVL) is braced to showcase multiple product offerings at OFC 2024, including probabilistic constellation...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter. "We ...
Marvell Technology Inc (NASDAQ:MRVL) has unveiled a significant development in semiconductor technology through an expanded partnership with&n...
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of...
U.S. stocks closed lower on Friday, following the release of jobs data for the month of February. All three major indices closed the week lower, wi...
News, Short Squeeze, Breakout and More Instantly...
Marvell Technology Inc. Company Name:
MRVL Stock Symbol:
NASDAQ Market:
Marvell Technology Inc. Website:
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
2024-07-15 18:00:00 ET Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) usually don't attract as much attention as higher-growth chipmakers like Nvidia (NASDAQ: NVDA) . But like Nvidia, both diversified chip specialists are benefiting from the rapid ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...